Zou Hanhui, Xia Liming, Jin Gu, Wu Hao, Qian Wenkang, Jia Dongdong, Xu Haichao, Li Tao
Bone and Soft Tissue Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, 310022, People's Republic of China.
Cancer Manag Res. 2022 May 11;14:1703-1711. doi: 10.2147/CMAR.S357334. eCollection 2022.
Retrospective study on the safety and efficacy of anlotinib in the treatment of advanced leiomyosarcoma in real-world.
Clinical data were collected from patients suffered from advanced leiomyosarcoma who received anlotinib treatment in Cancer Hospital of the University of Chinese Academy of Sciences from January 2018 to December 2020. Objective response rate (ORR) and disease control rate (DCR) were analyzed according to the RECIST 1.1 criteria. The progression free survival (PFS), overall survival (OS) and adverse reactions were recorded and calculated.
A total of 19 patients (14 female, 5 male) were enrolled, 3 (15.8%) achieved partial response (PR), 11 (57.9%) achieved stable disease (SD), with an ORR of 15.8%, a DCR of 73.7%, a median PFS of 4.1 months (95% CI: 3.05.2) and a median OS of 23.5 months (95% CI: 14.232.7). The majority of adverse events were grade 1/2, the most common grade 3/4 adverse events were hand-foot syndrome (12.5%), hypertension (5.3%) and oral ulcer (5.3%).
Our results forecast that anlotinib is effective, safe and alternative in treatment of advanced leiomyosarcoma in real-world, combined with immunotherapy may become a potential treatment option. Further, more prospective randomized controlled trials are needed to confirm these findings.
回顾性研究安罗替尼在真实世界中治疗晚期平滑肌肉瘤的安全性和有效性。
收集2018年1月至2020年12月在中国科学院大学附属肿瘤医院接受安罗替尼治疗的晚期平滑肌肉瘤患者的临床资料。根据RECIST 1.1标准分析客观缓解率（ORR）和疾病控制率（DCR）。记录并计算无进展生存期（PFS）、总生存期（OS）及不良反应。
共纳入19例患者（14例女性，5例男性），3例（15.8%）达到部分缓解（PR），11例（57.9%）病情稳定（SD），ORR为15.8%，DCR为73.7%，中位PFS为4.1个月（95%CI：3.05.2），中位OS为23.5个月（95%CI：14.232.7）。大多数不良事件为1/2级，最常见的3/4级不良事件为手足综合征（12.5%）、高血压（5.3%）和口腔溃疡（5.3%）。
我们的结果预示安罗替尼在真实世界中治疗晚期平滑肌肉瘤有效、安全且可作为替代方案，联合免疫治疗可能成为一种潜在的治疗选择。此外，需要更多前瞻性随机对照试验来证实这些发现。
